Patents by Inventor Waleed Danho

Waleed Danho has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180298066
    Abstract: The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimer's Disease or frontotemporal dementia.
    Type: Application
    Filed: June 27, 2018
    Publication date: October 18, 2018
    Inventors: John K. Bielicki, Jan Johansson, Waleed Danho
  • Patent number: 10017551
    Abstract: The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimer's Disease or frontotemporal dementia.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 10, 2018
    Assignee: The Regents of the University of California
    Inventors: John K. Bielicki, Jan Johansson, Waleed Danho
  • Patent number: 9416162
    Abstract: The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia and inflammation.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: August 16, 2016
    Assignee: The Regents of the University of California
    Inventors: John K. Bielicki, Jan Johansson, Waleed Danho
  • Patent number: 9409961
    Abstract: The present invention provides compounds to disrupt the eIF4E-eIF4G interaction and pharmaceutically acceptable salts of such compounds. Generally, the compounds are cell-penetrating peptides which bind mammalian initiation factor eIF4E (CPP-eIF4E), wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 7, 9-11, 12-26, 27-44 and 45-51. More preferably, the amino acid sequence comprises at least 9 to about 40 amino acids and the mammalian initiation factor eIF4E is human initiation factor eIF4E.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: August 9, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Waleed Danho, Nader Fotouhi, Yi Han, Wajiha Khan, Francesca Milletti, Huifeng Niu
  • Publication number: 20160031951
    Abstract: The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimer's Disease or frontotemporal dementia.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Inventors: John K. BIELICKI, Jan Johansson, Waleed Danho
  • Publication number: 20150166621
    Abstract: The present invention provides compounds to disrupt the eIF4E-eIF4G interaction and pharmaceutically acceptable salts of such compounds. Generally, the compounds are cell-penetrating peptides which bind mammalian initiation factor eIF4E (CPP-eIF4E), wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 7, 9-11, 12-26, 27-44 and 45-51. More preferably, the amino acid sequence comprises at least 9 to about 40 amino acids and the mammalian initiation factor eIF4E is human initiation factor eIF4E.
    Type: Application
    Filed: July 5, 2013
    Publication date: June 18, 2015
    Inventors: Waleed Danho, Nader Fotouhi, Yi Han, Wajiha Khan, Francesca Milletti, Huifeng Niu
  • Patent number: 9023986
    Abstract: The present invention provides compounds which are analogs of glucose-dependent insulinotropic polypeptide (GIP) and pharmaceutically acceptable salts of such compounds. These compounds have activity as agonists of GIP receptor.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: May 5, 2015
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Waleed Danho, George Ehrlich, Wajiha Khan, Joseph Swistok, Jefferson Wright Tilley
  • Publication number: 20140287994
    Abstract: The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia and inflammation.
    Type: Application
    Filed: March 17, 2014
    Publication date: September 25, 2014
    Applicant: The Regents of the University of California
    Inventors: John K. Bielicki, Jan Johansson, Waleed Danho
  • Patent number: 8299023
    Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): Y—R1—R2—X—R3—R4—R5—R6—R7—R8—R9—R10—R11—R12—R13—R14—NH2??(I) (SEQ ID NO: 1), as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.
    Type: Grant
    Filed: August 25, 2009
    Date of Patent: October 30, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Waleed Danho, David Charles Fry, Robert Alan Goodnow, Jr., Wajiha Khan, Joseph Swistok, Jefferson Wright Tilley
  • Patent number: 8268784
    Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. X is 4-oxo-6-(1-piperazinyl)-3(4H)-quinazoline-acetic acid (Pqa). These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: September 18, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Karin Conde-Knape, Waleed Danho, George Ehrlich, Nader Fotouhi, David Charles Fry, Wajiha Khan, Anish Konkar, Cristina Martha Rondinone, Joseph Swistok, Rebecca Anne Taub, Jefferson Wright Tilley
  • Publication number: 20120101037
    Abstract: The present invention provides compounds which are analogs of glucose-dependent insulinotropic polypeptide (GIP) and pharmaceutically acceptable salts of such compounds. These compounds have activity as agonists of GIP receptor.
    Type: Application
    Filed: October 17, 2011
    Publication date: April 26, 2012
    Inventors: Waleed Danho, George Ehrlich, Wajiha Khan, Joseph Swistok, Jefferson Wright Tilley
  • Publication number: 20110172147
    Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.
    Type: Application
    Filed: March 25, 2011
    Publication date: July 14, 2011
    Inventors: Karin Conde-Knape, Waleed Danho, Nader Fotouhi, David Charles Fry, Wajiha Khan, Anish Konkar, Cristina Martha Rondinone, Joseph Swistok, Jefferson Wright Tilley
  • Publication number: 20100179093
    Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.
    Type: Application
    Filed: November 2, 2009
    Publication date: July 15, 2010
    Inventors: Waleed Danho, Nader Fotouhi, David Charles Fry, Wajiha Khan, Joseph Swistok, Jefferson Wright Tilley
  • Publication number: 20100137223
    Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. X is 4-oxo-6-(1-piperazinyl)-3(4H)-quinazoline-acetic acid (Pqa). These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.
    Type: Application
    Filed: August 6, 2009
    Publication date: June 3, 2010
    Inventors: Karin Conde-Knape, Waleed Danho, George Ehrlich, Nader Fotouhi, David Charles Fry, Wajiha Khan, Anish Konkar, Cristina Martha Rondinone, Joseph Swistok, Rebecca Anne Taub, Jefferson Wright Tilley
  • Publication number: 20100069307
    Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): Y—R1—R2—X—R3—R4—R5—R6—R7—R8—R9—R10—R11—R12—R13—R14—NH2 ??(I), as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.
    Type: Application
    Filed: August 25, 2009
    Publication date: March 18, 2010
    Inventors: Waleed Danho, David Charles Fry, Robert Alan Goodnow, JR., Wajiha Khan, Joseph Swistok, Jefferson Wright Tilley
  • Patent number: 7642244
    Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. X is 4-oxo-6-(1-piperazinyl)-3(4H)-quinazoline-acetic acid (Pqa). These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: January 5, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Karin Conde-Knape, Waleed Danho, George Ehrlich, Nader Fotouhi, David Charles Fry, Wajiha Khan, Anish Konkar, Cristina Martha Rondinone, Joseph Swistok, Rebecca Anne Taub, Jefferson Wright Tilley
  • Patent number: 7410949
    Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): Y—R1—R2—X—R3—R4—R5—R6—R7—R8—R9—R10—R11—R12—R13—R14—NH2, ??(I) as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.
    Type: Grant
    Filed: January 10, 2006
    Date of Patent: August 12, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Waleed Danho, George Ehrlich, David C Fry, Wajiha Khan, Joseph Swistok
  • Publication number: 20080177036
    Abstract: Peptides of formulae I, II and III that selectively activate melanocortin-4 (MC-4) receptor activity.
    Type: Application
    Filed: March 14, 2008
    Publication date: July 24, 2008
    Inventors: Li Chen, Adrian Wai-Hing Cheung, Xin-Jie Chu, Waleed Danho, Joseph Swistok, Keith Alan Yagaloff
  • Publication number: 20070135351
    Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.
    Type: Application
    Filed: December 1, 2006
    Publication date: June 14, 2007
    Inventors: Karin Conde-Knape, Waleed Danho, George Ehrlich, Nader Fotouhi, David Fry, Wajiha Khan, Anish Konkar, Cristina Rondinone, Joseph Swistok, Rebecca Taub, Jefferson Tilley
  • Publication number: 20060160742
    Abstract: Provided herein are neuropeptide-2 receptor agonists of the formula (I): Y—R1—R2—X—R3—R4—R5—R6—R7—R8—R9—R10—R11—R12—R13—R14—NH2??(I), as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.
    Type: Application
    Filed: January 10, 2006
    Publication date: July 20, 2006
    Inventors: Waleed Danho, George Ehrlich, David Fry, Wajiha Khan, Joseph Swistok